The frequent amplification of HSF1 mRNA expression across many cancer types (Figure 2) [47,65] would provide higher levels of the target for any delivered homologous RNAi molecule compared to normal tissue, and thereby possibly increase the chances of a greater fold reduction of HSF1 expression. The gene discussed is HSF1; the disease is cancer.